Fulgent Genetics Inc
NASDAQ:FLGT

Watchlist Manager
Fulgent Genetics Inc Logo
Fulgent Genetics Inc
NASDAQ:FLGT
Watchlist
Price: 18.37 USD -1.66% Market Closed
Market Cap: 561.9m USD
Have any thoughts about
Fulgent Genetics Inc?
Write Note

Fulgent Genetics Inc
Depreciation & Amortization

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Fulgent Genetics Inc
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
Fulgent Genetics Inc
NASDAQ:FLGT
Depreciation & Amortization
-$7.9m
CAGR 3-Years
-115%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Quest Diagnostics Inc
NYSE:DGX
Depreciation & Amortization
-$117m
CAGR 3-Years
-4%
CAGR 5-Years
-4%
CAGR 10-Years
-3%
CVS Health Corp
NYSE:CVS
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cigna Corp
NYSE:CI
Depreciation & Amortization
-$1.7B
CAGR 3-Years
5%
CAGR 5-Years
6%
CAGR 10-Years
-28%
Laboratory Corporation of America Holdings
NYSE:LH
Depreciation & Amortization
-$245.2m
CAGR 3-Years
13%
CAGR 5-Years
-1%
CAGR 10-Years
-11%
R1 RCM Inc
NASDAQ:RCM
Depreciation & Amortization
-$1.9m
CAGR 3-Years
14%
CAGR 5-Years
12%
CAGR 10-Years
N/A
No Stocks Found

Fulgent Genetics Inc
Glance View

Market Cap
561m USD
Industry
Health Care

Fulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. The company is headquartered in Temple City, California and currently employs 645 full-time employees. The company went IPO on 2016-09-28. The firm develops a technology platform, which offers a test menu. The company performs full-gene sequencing with deletion/duplication analysis in single-gene tests; pre-established, multi-gene, disease-specific panels; and customized panels. Its test offerings also include Solid Tumor Molecular Profiling for somatic cancer testing, Rapid Whole Genome testing developed for children in neonatal intensive care units or pediatric intensive care units its Newborn Genetic Analysis panel, and a single front-line test designed to comprehensively detect ataxia-related variants. The company also offers certain research service tests, which are ordered by research institutions and other similar institutional customers.

FLGT Intrinsic Value
18.96 USD
Undervaluation 3%
Intrinsic Value
Price

See Also

What is Fulgent Genetics Inc's Depreciation & Amortization?
Depreciation & Amortization
-7.9m USD

Based on the financial report for Sep 30, 2024, Fulgent Genetics Inc's Depreciation & Amortization amounts to -7.9m USD.

What is Fulgent Genetics Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 3Y
-115%

Over the last year, the Depreciation & Amortization growth was 1%. The average annual Depreciation & Amortization growth rates for Fulgent Genetics Inc have been -115% over the past three years .

Back to Top